Healthcare / Medical DevicesTSXV
$1.71
-0.05 (-2.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-213038.00 · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$34M
P/E
N/A
•EV/EBITDA
N/A
•ROE
40.2%
↑Gross Margin
50.7%
↑Debt/Equity
-0.67
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+18.9%
FCF CAGR
—
FCF margin
-32.4%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.6M · net income $-1.3M · FCF $-508180.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $1.6M | $1.6M | $1.4M | $1.1M |
| Net Income | $-1.3M | $-1.3M | $-540838.00 | $-126464.00 |
| EBITDA | $-944178.00 | $-944178.00 | $-350924.00 | $36592.00 |
| EPS | — | — | -0.03 | -0.01 |
| Gross Margin | 50.7% | 50.7% | 53.7% | 52.7% |
| Operating Margin | -61.0% | -61.0% | -20.6% | 7.0% |
| Net Margin | -80.9% | -80.9% | -37.6% | -11.4% |
| Balance Sheet | ||||
| Debt/Equity | -0.67 | -0.67 | -0.68 | -0.62 |
| Current Ratio | 1.24 | 1.24 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-508180.00 | $-508180.00 | $-213038.00 | $-29886.00 |
| Returns | ||||
| ROE | 40.2% | 40.2% | 23.0% | 6.7% |
| Growth & Yield | ||||
| Revenue Growth | 9.2% | 9.2% | 29.5% | — |
| EPS Growth | — | — | -327.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+72.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → n/d
Residual
+72.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.